PRMT5 inhibitors can help treat advanced melanoma

Source: News Medical Life Sciences, July 2020

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

PRMT5 inhibitors are currently in clinical trials in oncology, and this research provides a strong rationale for evaluating the drugs in tumors that are not responsive to immune checkpoint therapy. The study was published in Science Translational Medicine.

“We found that inhibiting PRMT5 enhances both antigen presentation and the activation of innate immunity, prerequisites for effective immune checkpoint therapy."

READ THE ORIGINAL FULL ARTICLE